4/11
05:32 am
ptct
PTC Therapeutics (PTCT) was upgraded by Raymond James Financial, Inc. to "moderate buy".
Low
Report
PTC Therapeutics (PTCT) was upgraded by Raymond James Financial, Inc. to "moderate buy".
4/10
09:00 am
ptct
PTC Therapeutics (PTCT) is now covered by Raymond James Financial, Inc.. They set an "outperform" rating and a $108.00 price target on the stock.
Medium
Report
PTC Therapeutics (PTCT) is now covered by Raymond James Financial, Inc.. They set an "outperform" rating and a $108.00 price target on the stock.
4/10
05:35 am
ptct
PTC Therapeutics initiated with an Outperform at Raymond James
Medium
Report
PTC Therapeutics initiated with an Outperform at Raymond James
4/10
05:35 am
ptct
PTC Therapeutics initiated with an Outperform at Raymond James
Medium
Report
PTC Therapeutics initiated with an Outperform at Raymond James
4/9
04:30 pm
ptct
PTC Therapeutics initiated with an Outperform at Raymond James
Medium
Report
PTC Therapeutics initiated with an Outperform at Raymond James
4/9
04:30 pm
ptct
PTC Therapeutics initiated with an Outperform at Raymond James
Medium
Report
PTC Therapeutics initiated with an Outperform at Raymond James
3/30
11:50 am
ptct
Rating for PTCT
Low
Report
Rating for PTCT
3/30
11:50 am
ptct
Rating for PTCT
Low
Report
Rating for PTCT
2/23
11:16 am
ptct
Rating for PTCT
Low
Report
Rating for PTCT
2/23
11:16 am
ptct
Rating for PTCT
Low
Report
Rating for PTCT
2/23
08:03 am
ptct
PTC Therapeutics (NASDAQ:PTCT) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
PTC Therapeutics (NASDAQ:PTCT) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
2/23
08:03 am
ptct
PTC Therapeutics (NASDAQ:PTCT) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
PTC Therapeutics (NASDAQ:PTCT) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
2/23
07:01 am
ptct
PTC Therapeutics (NASDAQ:PTCT) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Low
Report
PTC Therapeutics (NASDAQ:PTCT) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
2/20
03:14 pm
ptct
PTC Therapeutics (NASDAQ:PTCT) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
PTC Therapeutics (NASDAQ:PTCT) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
2/20
12:54 pm
ptct
Rating for PTCT
Low
Report
Rating for PTCT
2/20
12:54 pm
ptct
Rating for PTCT
Low
Report
Rating for PTCT
2/20
09:42 am
ptct
Rating for PTCT
Low
Report
Rating for PTCT
2/20
09:42 am
ptct
Rating for PTCT
Low
Report
Rating for PTCT
2/20
09:03 am
ptct
PTC Therapeutics (NASDAQ:PTCT) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
PTC Therapeutics (NASDAQ:PTCT) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
2/20
09:03 am
ptct
PTC Therapeutics (NASDAQ:PTCT) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
PTC Therapeutics (NASDAQ:PTCT) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
1/28
09:46 am
ptct
Rating for PTCT
Low
Report
Rating for PTCT
1/28
09:46 am
ptct
Rating for PTCT
Low
Report
Rating for PTCT
1/27
06:00 pm
ptct
PTC Therapeutics (NASDAQ:PTCT) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating.
Low
Report
PTC Therapeutics (NASDAQ:PTCT) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating.